Phase II study of anti-cancer activity of metformin patients with advanced solid tumors
- Conditions
- Neoplasms
- Registration Number
- KCT0005210
- Lead Sponsor
- ational Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 188
1.cytologically or histologically confirmed diagnosis of nonsmall cell lung cancer or small cell lung cancer
2.18 years of age or older
3.a performance status (PS) of = 2 on the Eastern Cooperative Oncology Group (ECOG) scale
4.at least one measurable or evaluable tumour lesion
5.adequate organ function and normal hematologic function
1.previous systemic chemotherapy (ex: monoclonal antibody)
2.previous radiation therapy without no progression on target lesions within radiation portal.
3.Active interstitial lung disease (radiation change without symptom would be permitted)
4.Invasive malignant tumor history within 5 years except skin basal carcinoma. Cervical in situ carcinoma, and thyroid cancer
5.Brain metastasis or leptomeningeal carcinomatosis requiring steroid with neurologic abnormality
6.History of metformin administration within 3 months
7.Known EGFR mutations
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression-free survival
- Secondary Outcome Measures
Name Time Method overall survival